Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .
Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study.
OBJECTIVE To assess combined antidepressant and cognitive enhancer treatment in elderly patients presenting with depression plus cognitive impairment . METHODS Twenty-three elderly ( > 50 years old ) depressed , cognitively impaired ( DEP-CI ) patients participated in a pilot study . We evaluated whether , after 8 weeks of open antidepressant treatment , donepezil HCl ( Aricept ) would afford added cognitive benefit compared to placebo in a r and omized 12-week trial . A sub sample continued in an 8-month extension phase of open treatment with donepezil . Neuropsychological testing ( NPT ) was performed and  antidepressant response monitored at baseline and the 8 , 20 , and 52-week time points . RESULTS At 8-weeks , the  antidepressant response rate was 61 % ( 14/23 ) . Improvement in SRT immediate recall ( SRT-IR ; e.g. episodic verbal memory ) was observed in responders compared to non-responders . During the 12-week , placebo-controlled , donepezil add-on trial , patients on donepezil showed further improvement in SRT-IR versus patients on placebo . In the open extension phase , patients who continued open donepezil treatment ( n = 6 ) maintained improvement in memory and tended to show an advantage over patients who never received donepezil and were evaluated at the 52-week time point ( n = 6 ) . There were no observed significant donepezil effects on non-memory cognitive domains . CONCLUSION These preliminary findings suggest that addition of a cholinesterase inhibitor ( AChEI ) following antidepressant medication treatment in elderly Dep-CI patients may improve cognition , and support the need for a confirmatory , larger r and omized placebo-controlled trial
Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains .
Specifically , studies suggest that SSRIs , the SSRE tianeptine , the SNRI duloxetine , vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression , such as in learning and memory and executive function .
The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression .
Cognitive dysfunction is of clinical significance and exerts longst and ing implication on patients ׳ function .
Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging .
This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory , attention , processing speed and executive function in clinical depression .